The ventilator foam degradation lawsuit centers on a massive recall issued by Philips Respironics in June 2021, after the company acknowledged that PE-PUR (polyester-based polyurethane) sound-abatement foam inside its CPAP, BiPAP, and mechanical ventilator devices could break down and release toxic particles and gases directly into the airways of users. A $1.1 billion settlement was reached in April 2024, with $1.075 billion allocated toward personal injury and death claims, though federal court approval remains pending as of February 2026. Estimated individual payouts range from $7,500 to $10,000 for less severe cases, and potentially $100,000 to $500,000 or more for claimants who developed lung cancer or significant pulmonary conditions.
Consider a sleep apnea patient who used a Philips DreamStation CPAP machine nightly for years, only to discover that degraded black foam particles had been flowing into the air they breathed each night. That scenario is not hypothetical — the FDA has received over 116,000 medical device reports tied to PE-PUR foam breakdown, including 561 reports of death. This article covers the full scope of the litigation, from what triggered the recall to the current status of MDL 3014, the health risks identified, the settlement structure, FDA enforcement actions, and what affected device users should know going forward.
Table of Contents
- What Caused the Ventilator Foam Degradation Lawsuit Against Philips?
- Health Risks Linked to Degraded PE-PUR Foam in CPAP and Ventilator Devices
- Where the MDL Stands — Current Litigation in the Western District of Pennsylvania
- What the $1.1 Billion Settlement Means for Claimants
- FDA Enforcement and the Consent Decree Against Philips
- The February 2025 Recall Expansion and What It Signals
- What Comes Next for the Philips Ventilator Foam Litigation
- Conclusion
- Frequently Asked Questions
What Caused the Ventilator Foam Degradation Lawsuit Against Philips?
The root of this litigation is the PE-PUR foam that philips Respironics used as a sound-dampening component in a wide range of breathing devices. The foam was intended to reduce noise from the machines, but over time — and especially when exposed to heat, humidity, and certain cleaning products like ozone — it degraded. That degradation released black particles and volatile organic compounds directly into the device’s airway, meaning users were inhaling or swallowing toxic material during sleep therapy or ventilator use. Philips issued its initial recall in June 2021, covering millions of devices worldwide. But the problems did not end there.
In February 2025, Philips expanded the recall to include certain Trilogy EVO ventilators, affecting 215 ventilators and 51 repair kits in the United States that were manufactured between April 15 and May 24, 2021. This expansion underscored that even after years of remediation efforts, new device populations were still being identified as affected. What makes this case particularly damaging from a litigation standpoint is the nature of the exposure. Unlike a defective hip implant or a contaminated drug that a patient might take once, cpap and BiPAP users typically rely on these devices for hours every single night. That prolonged, repeated exposure to degraded foam particles created a cumulative risk profile that plaintiffs’ attorneys have argued Philips should have anticipated and disclosed far earlier than it did.
Health Risks Linked to Degraded PE-PUR Foam in CPAP and Ventilator Devices
The degraded foam can release both solid black particles and volatile organic compounds into the airstream of the device. When a user breathes through a contaminated machine, those particles and chemicals enter the respiratory system directly. Alleged health effects cited in the litigation include cancer, inflammatory disease, severe respiratory illness, persistent headaches, and organ damage. Some claimants have reported developing conditions that required hospitalization or long-term medical treatment after years of nightly device use. However, it is worth noting that establishing a direct causal link between foam degradation and a specific individual’s illness is one of the more complex aspects of this litigation.
Many CPAP users have underlying health conditions — sleep apnea itself is associated with cardiovascular risk, and some claimants are older adults with multiple comorbidities. If a claimant developed respiratory issues but also had a history of smoking or occupational chemical exposure, proving that the Philips device was the primary cause becomes more difficult. This is partly why the settlement tiers vary so dramatically, with severe, well-documented cases potentially receiving $100,000 to $500,000 or more, while less severe or harder-to-prove claims may receive $7,500 to $10,000. The FDA’s own data paints a stark picture regardless. Over 116,000 medical device reports and 561 death reports associated with the recalled devices represent one of the larger medical device safety signals in recent years. Those numbers alone have provided substantial ammunition for the plaintiffs’ side of the case.
Where the MDL Stands — Current Litigation in the Western District of Pennsylvania
All federal cases related to this recall have been consolidated into multidistrict litigation designated as MDL 3014, housed in the Western District of Pennsylvania before Senior U.S. District Judge Joy Flowers Conti. As of February 2026, 618 pending cases remain in the MDL. This consolidation allows for coordinated pretrial proceedings, shared discovery, and the potential for bellwether trials that would test key legal theories before a jury. No bellwether trial verdicts have been issued yet.
The $1.1 billion settlement reached on April 29, 2024, was intended to resolve the personal injury track, but because federal court approval is still pending, the litigation remains in a holding pattern. If the settlement is ultimately not approved — or if a significant number of claimants opt out — bellwether trials could proceed. Those trials would serve as test cases, and their outcomes would likely influence any subsequent settlement negotiations or individual trial strategies. For context, MDL proceedings are common in mass tort cases involving defective products, and this one is among the larger active MDLs in the federal system. The sheer volume of medical device reports to the FDA, combined with the broad scope of the recall covering devices used by millions of people, ensures that this litigation will continue to draw attention from both the legal community and affected consumers for the foreseeable future.
What the $1.1 Billion Settlement Means for Claimants
The settlement announced on April 29, 2024, allocated $1.075 billion specifically toward injury and death claims. The tiered payout structure reflects the reality that not all claimants suffered the same degree of harm. Individuals with documented diagnoses of lung cancer or other significant pulmonary conditions linked to device use could receive $100,000 to $500,000 or more. Those with less severe claims — perhaps persistent headaches, mild respiratory symptoms, or anxiety over potential exposure without a diagnosed illness — are looking at estimated payouts in the $7,500 to $10,000 range. The tradeoff for claimants is familiar in mass tort settlements: accept a guaranteed payment now, or hold out for a potentially larger verdict at trial with the risk of receiving nothing.
Opting into a settlement means giving up the right to pursue an individual lawsuit against Philips. For someone with a clear-cut severe injury, that calculus might favor waiting for trial — particularly if bellwether cases produce favorable verdicts. For someone with a more modest claim, the certainty of a settlement payment, even a smaller one, may be the pragmatic choice. One important caveat: because federal court approval is still pending as of February 2026, no settlement payments have been distributed yet. Claimants should be cautious about any third-party entity promising accelerated payouts or requiring upfront fees. The approval process in a settlement of this magnitude involves judicial review of the fairness and adequacy of the terms, and that process takes time.
FDA Enforcement and the Consent Decree Against Philips
Beyond the civil litigation, Philips Respironics has faced significant regulatory consequences. On April 9, 2024, a federal court entered a consent decree against the company, requiring implementation of a Recall Remediation Plan. This is a serious enforcement action — consent decrees in the medical device space essentially place the company under court-supervised compliance obligations, and violations can result in contempt findings and additional penalties. Philips has reported remediating 99% of actionable sleep therapy device registrations globally. Device registration in the United States and Canada closed on December 31, 2024, and the U.S.
Patient Portal was taken offline on January 1, 2026. These closures mean that users who have not yet registered their recalled devices or sought remediation through official channels have limited options going forward. This is a critical limitation that affected users should understand. The window for registering a recalled device and receiving a replacement or repair through Philips’ own program has effectively closed in North America. That does not necessarily bar someone from participating in the legal settlement — those are separate processes — but it does mean that the company’s direct remediation infrastructure is winding down. Anyone who still has an unregistered recalled device should consult with a legal professional about their options rather than assuming they have missed all deadlines.
The February 2025 Recall Expansion and What It Signals
In February 2025, Philips expanded the recall to include certain Trilogy EVO ventilators — 215 devices and 51 repair kits manufactured during a narrow window in spring 2021. While relatively small in scale compared to the original recall, this expansion is significant because it demonstrates that the foam degradation issue was not limited to consumer-facing CPAP machines. The Trilogy EVO is a life-sustaining ventilator used by patients with serious respiratory conditions, many of whom have no alternative but to rely on mechanical ventilation.
For these patients, the stakes of foam degradation are even higher. A CPAP user with sleep apnea can, in an emergency, stop using the device temporarily. A ventilator-dependent patient cannot simply go without their machine while waiting for a replacement. This created an agonizing dilemma for patients and their caregivers, and it is one of the factors that has driven the urgency of both the regulatory response and the legal proceedings.
What Comes Next for the Philips Ventilator Foam Litigation
The most consequential near-term development will be whether the federal court grants final approval of the $1.1 billion settlement. If approved, the claims administration process will begin, and payments will start flowing to eligible claimants — though the timeline for individual disbursements could stretch months or even years given the volume of claims. If the settlement is rejected or substantially modified, the case reverts to a litigation footing, and bellwether trials would likely be scheduled.
Looking further ahead, this case may have lasting implications for how medical device manufacturers handle sound-abatement and material-safety testing in respiratory equipment. The FDA’s aggressive enforcement posture, including the consent decree, signals that regulators will not treat foam degradation or similar latent defects lightly. For the millions of people who depend on CPAP, BiPAP, and ventilator technology, the Philips case has been a sobering reminder that even routine medical devices carry risks — and that manufacturers have an obligation to identify and disclose those risks before patients are harmed.
Conclusion
The Philips Respironics ventilator and CPAP foam degradation lawsuit is one of the most significant medical device litigations in recent memory. With over 116,000 medical device reports filed with the FDA, 561 reported deaths, a $1.1 billion proposed settlement, and 618 cases still pending in MDL 3014, the scope of this case reflects both the scale of the recall and the severity of the alleged injuries. The consent decree, the recall expansions, and the closure of device registration portals all point to a case that is entering its final chapters — but not one that is resolved yet.
If you used a recalled Philips CPAP, BiPAP, or ventilator device and have experienced respiratory problems, headaches, or other health issues, the most important step you can take right now is to speak with an attorney who handles mass tort or medical device cases. The settlement approval process is ongoing, and individual eligibility depends on factors including the specific device used, the duration of use, and the nature of any diagnosed medical conditions. Do not rely on the Philips patient portal, which is no longer active in the U.S. — legal counsel can help you understand what options remain available.
Frequently Asked Questions
What devices are included in the Philips CPAP and ventilator recall?
The recall covers a broad range of Philips Respironics CPAP, BiPAP, and mechanical ventilator devices that used PE-PUR sound-abatement foam. The most recent expansion in February 2025 added certain Trilogy EVO ventilators manufactured between April 15 and May 24, 2021.
How much money could I receive from the Philips CPAP settlement?
Estimated payouts range from $7,500 to $10,000 for less severe cases to $100,000 to $500,000 or more for claimants with serious conditions such as lung cancer or significant pulmonary disease. The exact amount depends on the severity and documentation of your injuries.
Has the $1.1 billion Philips settlement been approved by the court?
No. As of February 2026, federal court approval is still pending. No settlement payments have been distributed yet.
Can I still register my recalled Philips device?
Device registration in the United States and Canada closed on December 31, 2024, and the U.S. Patient Portal was taken offline on January 1, 2026. However, you may still be eligible to participate in the legal settlement — consult an attorney for guidance.
What health problems are associated with the degraded foam?
Alleged health effects include cancer, inflammatory disease, severe respiratory illness, headaches, and organ damage. The degraded PE-PUR foam can release black particles and volatile organic compounds into the device airway.
Where is the Philips CPAP lawsuit being handled?
The cases are consolidated in multidistrict litigation (MDL 3014) in the Western District of Pennsylvania, before Senior U.S. District Judge Joy Flowers Conti. As of February 2026, 618 cases remain pending.